Bukwang Pharmaceutical Co., Ltd. (003000.KS)
KRW 4745.0
(-1.35%)
KRW 4745.0
(-1.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -30.56 Billion KRW | -598.11% |
| 2022 | 5.78 Billion KRW | -32.52% |
| 2021 | 11.39 Billion KRW | 46.52% |
| 2020 | 2.21 Billion KRW | -60.34% |
| 2019 | 5.35 Billion KRW | -56.68% |
| 2018 | 197.93 Billion KRW | 187.47% |
| 2017 | 20.98 Billion KRW | -48.51% |
| 2016 | 26.72 Billion KRW | 6.66% |
| 2015 | 28.41 Billion KRW | -26.98% |
| 2014 | 34.03 Billion KRW | 2.1% |
| 2013 | 30.62 Billion KRW | 2.01% |
| 2012 | 32.62 Billion KRW | 110.19% |
| 2011 | 14.3 Billion KRW | -66.61% |
| 2010 | 47.39 Billion KRW | 9.99% |
| 2009 | 42.23 Billion KRW | -7.23% |
| 2008 | 45.62 Billion KRW | -8.51% |
| 2007 | 50.05 Billion KRW | 68.29% |
| 2006 | 29.98 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 3.17 Billion KRW | 18.22% |
| 2024 Q1 | -1.62 Billion KRW | 94.87% |
| 2024 Q2 | -2.54 Billion KRW | 500.85% |
| 2023 Q1 | 17.01 Billion KRW | 164.86% |
| 2023 FY | - KRW | -598.11% |
| 2023 Q2 | 170.82 Million KRW | -99.0% |
| 2023 Q3 | 6.21 Billion KRW | 3540.0% |
| 2023 Q4 | -14.52 Billion KRW | -333.61% |
| 2022 Q2 | 539.53 Million KRW | 159.3% |
| 2022 Q1 | -909.91 Million KRW | -115.02% |
| 2022 FY | - KRW | -32.52% |
| 2022 Q3 | -210.59 Million KRW | -139.03% |
| 2022 Q4 | 6.42 Billion KRW | 3150.87% |
| 2021 FY | - KRW | 46.52% |
| 2021 Q1 | -936.02 Million KRW | 86.26% |
| 2021 Q3 | 4.21 Billion KRW | 501.71% |
| 2021 Q2 | 700.81 Million KRW | 174.87% |
| 2021 Q4 | 6.05 Billion KRW | 43.63% |
| 2020 Q1 | 2.18 Billion KRW | 146.69% |
| 2020 Q3 | 1.51 Billion KRW | -38.84% |
| 2020 Q4 | -6.81 Billion KRW | -549.28% |
| 2020 Q2 | 2.47 Billion KRW | 13.24% |
| 2020 FY | - KRW | -60.34% |
| 2019 Q3 | -2.08 Billion KRW | -154.2% |
| 2019 Q4 | -4.68 Billion KRW | -125.22% |
| 2019 Q1 | 3.06 Billion KRW | 81.69% |
| 2019 FY | - KRW | -56.68% |
| 2019 Q2 | 3.84 Billion KRW | 25.23% |
| 2018 FY | - KRW | 187.47% |
| 2018 Q3 | 31.78 Billion KRW | 496.2% |
| 2018 Q4 | 1.68 Billion KRW | -94.69% |
| 2018 Q2 | 5.33 Billion KRW | -10.07% |
| 2018 Q1 | 5.92 Billion KRW | 152.39% |
| 2017 Q3 | 5.24 Billion KRW | 187.07% |
| 2017 Q1 | 4.26 Billion KRW | 541.8% |
| 2017 Q2 | 1.82 Billion KRW | -57.23% |
| 2017 FY | - KRW | -48.51% |
| 2017 Q4 | 2.34 Billion KRW | -55.17% |
| 2016 Q3 | 1.01 Billion KRW | -85.14% |
| 2016 FY | - KRW | 6.66% |
| 2016 Q2 | 6.86 Billion KRW | 68.22% |
| 2016 Q4 | -966.07 Million KRW | -194.77% |
| 2016 Q1 | 4.07 Billion KRW | -32.2% |
| 2015 Q4 | 6.01 Billion KRW | -18.1% |
| 2015 Q2 | 6.97 Billion KRW | -13.73% |
| 2015 FY | - KRW | -26.98% |
| 2015 Q3 | 7.34 Billion KRW | 5.38% |
| 2015 Q1 | 8.08 Billion KRW | 24.7% |
| 2014 Q4 | 6.48 Billion KRW | -26.99% |
| 2014 Q2 | 8.18 Billion KRW | -21.93% |
| 2014 Q1 | 10.48 Billion KRW | 22.96% |
| 2014 Q3 | 8.87 Billion KRW | 8.38% |
| 2014 FY | - KRW | 2.1% |
| 2013 Q4 | 8.53 Billion KRW | -4.97% |
| 2013 FY | - KRW | 2.01% |
| 2013 Q2 | 6.31 Billion KRW | -8.32% |
| 2013 Q1 | 6.88 Billion KRW | -39.72% |
| 2013 Q3 | 8.97 Billion KRW | 42.12% |
| 2012 Q2 | 6.63 Billion KRW | 138.11% |
| 2012 Q3 | 11.08 Billion KRW | 67.09% |
| 2012 FY | - KRW | 110.19% |
| 2012 Q1 | 2.78 Billion KRW | 0.0% |
| 2012 Q4 | 11.42 Billion KRW | 3.07% |
| 2011 Q3 | 7.77 Billion KRW | -26.16% |
| 2011 Q2 | 10.53 Billion KRW | -37.29% |
| 2011 Q1 | 16.79 Billion KRW | 78.42% |
| 2011 FY | - KRW | -66.61% |
| 2010 FY | - KRW | 9.99% |
| 2010 Q3 | 12.17 Billion KRW | 48.79% |
| 2010 Q4 | 9.41 Billion KRW | -22.66% |
| 2010 Q2 | 8.18 Billion KRW | -13.65% |
| 2010 Q1 | 9.47 Billion KRW | -20.85% |
| 2009 Q4 | 11.96 Billion KRW | 11.89% |
| 2009 FY | - KRW | -7.23% |
| 2009 Q1 | - KRW | -100.0% |
| 2009 Q2 | 10.19 Billion KRW | 0.0% |
| 2009 Q3 | 10.69 Billion KRW | 4.95% |
| 2008 FY | - KRW | -8.51% |
| 2008 Q2 | 9.84 Billion KRW | 0.0% |
| 2008 Q3 | 12 Billion KRW | 21.99% |
| 2008 Q4 | 9.64 Billion KRW | -19.67% |
| 2008 Q1 | - KRW | -100.0% |
| 2007 Q2 | 9.9 Billion KRW | 0.0% |
| 2007 Q4 | 14.36 Billion KRW | 9.02% |
| 2007 FY | - KRW | 68.29% |
| 2007 Q3 | 13.17 Billion KRW | 33.1% |
| 2006 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 729.192% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 121.624% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 52.264% |
| HANDOK Inc. | 35.06 Billion KRW | 187.172% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | -2848.97% |
| Yuhan Corporation | 127.43 Billion KRW | 123.988% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 181.47% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | -40.949% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 109.454% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | 712.551% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 302.195% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | 993.555% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | 775.333% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 186.141% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 729.192% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | -65.486% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | 566.338% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 37.985% |
| JW Holdings Corporation | 187.88 Billion KRW | 116.27% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 40.33% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 110.778% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 134.261% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 17.532% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 331.41% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 358.443% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 263.863% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 729.192% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 155.606% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 118.536% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 134.261% |
| Yuhan Corporation | 127.43 Billion KRW | 123.988% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 191.314% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 499.594% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 139.684% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 134.261% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 183.441% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 143.188% |
| CKD Bio Corp. | -1.63 Billion KRW | -1774.845% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 161.391% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 193.879% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 183.043% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 17.532% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 149.079% |
| Boryung Corporation | 114.28 Billion KRW | 126.747% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 302.195% |
| JW Lifescience Corporation | 50.82 Billion KRW | 160.139% |